Why menisci show higher healing rate when repaired during ACL reconstruction? Growth factors release can be the explanation
- 886 Downloads
Healing rate of meniscus repair is higher when the suture is associated with anterior cruciate ligament reconstruction. A possible explanation can be a different pattern of release of growth factors between anterior cruciate ligament reconstruction and isolated meniscus surgery. Hypothesis of this study is that the concentrations of bFGF, TGF-β and platelet-derived growth factor (PDGF) in joint fluid, immediately after single-bundle anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy, can be different.
Twenty consecutive patients underwent partial medial meniscectomy and twenty consecutive patients underwent single-bundle anterior cruciate ligament reconstruction with hamstring grafts were enrolled in the study. Thirty minutes after the end of the surgical procedure, a sample of joint fluid, as well of venous blood, was collected from all the patients. Concentrations of growth factors were determined by enzyme-linked immunosorbent assay.
The peripheral blood concentration of TGF-β, bFGF and PDGF was comparable between partial meniscectomy and anterior cruciate ligament reconstruction groups. No differences between the two surgical techniques were also found in term of TGF-β and bFGF joint fluid concentration, whereas joint PDGF concentration of anterior cruciate ligament reconstruction patients was significantly higher than the one found in partial meniscectomy patients.
A significant growth factors release was detected in the knee joint during arthroscopic surgery. PDGF concentration was significantly higher in anterior cruciate ligament reconstructed knee than in the meniscectomy group. PDGF can play an important role enhancing the healing response of meniscus suture and can be one of the biological reasons of the higher meniscal healing rate in anterior cruciate ligament reconstructed knee.
KeywordsMeniscal repair ACL reconstruction Platelet-derived growth factor Basic fibroblastic growth factor Transforming growth factor-β Tissue healing Tissue remodelling
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Arnoczky SP, Warren RF (1982) Microvasculature of the human meniscus. Am J Sports Med 10:90–95Google Scholar
- 11.Galliera E, de Girolamo L, Randelli P, Volpi P, Dogliotti G, Quaglia A, Banfi G, Cabitza P, Corsi MM, Denti M (2011) High articular levels of the angiogenetic factors VEGF (Vascular Endothelial Growth Factor) and VEGF-Receptor 2 as tissue healing biomarkers after single bundle anterior cruciate ligament reconstruction. J Biol Regul Homeost Agents 25:85–91PubMedGoogle Scholar
- 13.Henning CE, Lynch MA, Yearout KM, Vequist SW, Stallbaumer RJ, Decker KA (1990) Arthroscopic meniscal repair using an exogenous fibrin clot. Clin Orthop Relat Res 252:64–72Google Scholar
- 20.Meister K, Indelicato PA, Spanier S, Franklin J, Batts J (2004) Histology of the torn meniscus: a comparison of histologic differences in meniscal tissue between tears in anterior cruciate ligament-intact and anterior cruciate ligament-deficient knees. Am J Sports Med 32:1479–1483PubMedCrossRefGoogle Scholar
- 26.Popescu D, Sastre S, Garcia AI, Tomas X, Reategui D, Caballero M (2013) MR-arthrography assessment after repair of chronic meniscal tears. Knee Surg Sports Traumatol Arthrosc. (Epub ahead of print)Google Scholar
- 40.Tandogan RN, Taşer O, Kayaalp A, Taşkiran E, Pinar H, Alparslan B, Alturfan A (2004) Analysis of meniscal and chondral lesions accompanying anterior cruciate ligament tears: relationship with age, time from injury, and level of sport. Knee Surg Sports Traumatol Arthrosc 12:262–270PubMedCrossRefGoogle Scholar
- 42.Toman CV, Dunn WR, Spindler KP, Amendola A, Andrish JT, Bergfeld JA, Flanigan D, Jones MH, Kaeding CC, Marx RG, Matava MJ, McCarty EC, Parker RD, Wolcott M, Vidal A, Wolf BR, Huston LJ, Harrell FE Jr, Wright RW (2009) Success of meniscal repair at anterior cruciate ligament reconstruction. Am J Sports Med 37:1111–1115PubMedCentralPubMedCrossRefGoogle Scholar
- 45.Wieman TJ, Smiell JM, Su Y (1998) Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 21:822–827PubMedCrossRefGoogle Scholar